교모세포종 또는 비소세포폐암 환자를 대상으로 한 BDTX-1535 연구
교모세포종 또는 비소세포폐암 환자를 대상으로 경구용 EGFR 억제제인 BDTX-1535를 평가하기 위한 1상 연구
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.
Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: BDTX Clinical Trial Navigation Service
- 전화번호: (866) 955-4397
- 이메일: blackdiamondtx@careboxhealth.com
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 모병
- University of Alabama
-
연락하다:
- Anna Wilbanks
- 전화번호: 205-934-6454
- 이메일: annaburton@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, 미국, 85234
- 모병
- Banner MD Anderson Cancer Center
-
연락하다:
- Brandi Luzania
- 전화번호: 480-256-5488
- 이메일: Brandi.Luzania@bannerhealth.com
-
-
California
-
Irvine, California, 미국, 92618
- 모병
- City of Hope Orange County Lennar Foundation Cancer Center
-
연락하다:
- 전화번호: 626-218-1133
-
연락하다:
- Diana Patterson
- 전화번호: 949-671-4763
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars Sinai Medical Center
-
연락하다:
- Garret Crook
- 전화번호: 424-314-0745
- 이메일: Garrett.Crook@cshs.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20016
- 모병
- Sibley Memorial Hospital Johns Hopkins Medicine
-
연락하다:
- Judith Lawrence
- 전화번호: 202-660-6500
- 이메일: sibleyoncresreferral@live.johnshopkins.edu
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- 모병
- Mayo Clinic- Jacksonville
-
연락하다:
- Yanyan Lou
- 전화번호: 855-776-0015
-
Miami, Florida, 미국, 33176
- 모병
- Miami Cancer Institute - Baptist Health South Florida
-
연락하다:
- Xiaoou Pan
- 전화번호: 785-594-7856
- 이메일: Xiaoou.pan@baptisthealth.net
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- 모병
- UHP- University of Hawaii Cancer Center
-
연락하다:
- Evan Wu, MD
- 전화번호: 808-586-3010
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
연락하다:
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 모병
- Dana-Farber Cancer Institute
-
연락하다:
- Dawn Bissessar
- 전화번호: 617-632-5119
- 이메일: dawn_bissessar@dfci.harvard.edu
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic- Rochester
-
연락하다:
- Anastasios Dimou, MD
- 전화번호: 855-776-0015
-
-
New York
-
The Bronx, New York, 미국, 10461
- 모병
- Montefiore Medical Center
-
연락하다:
- Balazs Halmos, MD
- 전화번호: 718-405-8404
- 이메일: bahalmos@montefiore.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- 모병
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
연락하다:
- Jennifer Ruth
- 이메일: ruthj2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Tennessee Oncology
-
연락하다:
- Melissa Johnson, MD
- 전화번호: 615-320-5090
- 이메일: melissa.johnson@scri.com
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- Inova Schar Cancer Institute
-
연락하다:
- Stephanie Van Bebber
- 전화번호: 571-472-0213
- 이메일: Stephanie.VanBebber@inova.org
-
Fairfax, Virginia, 미국, 22031
- 모병
- Next Oncology
-
연락하다:
- Rebecca Fisher
- 이메일: rfisher@nextoncology.com
-
-
Washington
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center/University of Washington
-
연락하다:
- Sam Woodman
- 전화번호: 206-606-6346
- 이메일: swoodman@fredhutch.org
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- 모병
- BC Cancer Vancouver
-
연락하다:
- Vishaldeep Sidhu
- 전화번호: 236-994-8251
- 이메일: ClinicalTrialsHelp@bccancer.bc.ca
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1X5
- 모병
- The Princess Margaret Cancer Centre
-
연락하다:
- Tuhina Paul
- 전화번호: 416-946-4501 x 7890
- 이메일: Tuhina.Paul@uhn.ca
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Phase 2 Eligibility:
Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:
-
Measurable disease by RECIST 1.1 criteria.
-
Adequate bone marrow or organ function.
-
Life expectancy of ≥ 3 months.
-
Sufficient performance status.
-
Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
-
Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):
- Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
- Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
- Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
-
Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):
- Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
- EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
- For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
Key Exclusion Criteria:
- Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
- Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
- Any history of interstitial lung disease related to EGFR TKI use.
- Symptomatic or radiographic leptomeningeal disease.
- Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
- Unresolved toxicity from prior therapy.
- Significant cardiovascular disease.
- Major surgery within 4 weeks of study entry or planned during study.
- Ongoing or recent anticancer therapy or radiation therapy.
- Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
- Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
- Poorly controlled gastrointestinal disorders.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
|
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
다른 이름들:
|
|
실험적: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
다른 이름들:
|
|
실험적: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)
Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
다른 이름들:
|
|
실험적: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
다른 이름들:
|
|
실험적: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
기간: The first treatment 21-day cycle (Cycle 1)
|
Dose-limiting toxicities (DLTs) in Cycle 1 |
The first treatment 21-day cycle (Cycle 1)
|
|
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
기간: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
|
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
기간: Through study completion, approximately 1 year
|
Treatment-emergent adverse events |
Through study completion, approximately 1 year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
2단계: RECIST 버전 1.1을 통해 무진행 생존율을 평가합니다.
기간: 1일차 주기 3부터 시작하여 2주기마다 1일차부터 연구 완료까지, 약 1년(각 주기는 21일)
|
1일차 주기 3부터 시작하여 2주기마다 1일차부터 연구 완료까지, 약 1년(각 주기는 21일)
|
|
|
1 단계 : RECIST 버전 1.1 (NSCLC 환자) 또는 신경 종양학 (RANO)의 반응 평가 (GBM 환자)에 의해 평가 된 객관적인 반응에 의해 객관적인 반응에 의해 Silevertinib (BDTX-1535)의 예비 항 종양 활성을 평가한다.
기간: 주기 3 일 1 일부터 시작하여 1 일마다 1 일 1 일마다 약 1 년 (각주기는 21 일)
|
주기 3 일 1 일부터 시작하여 1 일마다 1 일 1 일마다 약 1 년 (각주기는 21 일)
|
|
|
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
기간: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Black Diamond Therapeutics, Black Diamond Therapeutics
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
- EGFR 억제제
- 뇌 전이
- EGFR L858R
- CNS 전이
- 두개내 질환
- EGFR 변경
- 중추 신경계 전이
- EGFR 엑손 19 델
- 내인성 저항성 NSCLC EGFR
- 획득 저항성 NSCLC EGFR
- 흔하지 않은 NSCLC EGFR 돌연변이
- C797S 획득 저항성 EGFR 돌연변이
- 비고전적 NSCLC EGFR 돌연변이
- 고전적 NSCLC EGFR 돌연변이
- 두 번째 부위 EGFR 돌연변이
- EGFR PACC NSCLC 돌연변이
- EGFR E709A/G/K/Q/V
- EGFR E709_T710delinsD/T
- EGFR G719A/C/D/R/S
- EGFR G724S
- EGFR L718Q/V
- EGFR L747S/P, L747_A750delinsP, L747_P753delinsS
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- BDTX-1535-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .